Compare TIRX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIRX | BCTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 18.5M |
| IPO Year | 2021 | N/A |
| Metric | TIRX | BCTX |
|---|---|---|
| Price | $0.77 | $11.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 128.9K | 48.6K |
| Earning Date | 08-22-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 158.74 | N/A |
| 52 Week Low | $0.60 | $6.00 |
| 52 Week High | $6.45 | $190.50 |
| Indicator | TIRX | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 56.50 |
| Support Level | $0.75 | $9.25 |
| Resistance Level | $1.10 | $13.00 |
| Average True Range (ATR) | 0.12 | 0.99 |
| MACD | 0.03 | 0.43 |
| Stochastic Oscillator | 33.78 | 73.48 |
Tian Ruixiang Holdings Ltd is an Insurance Brokerage firm. It distributes a wide range of insurance products, which are categorized into two groups; property and casualty insurance, such as commercial property insurance, liability insurance, accidental insurance, and automobile insurance; and other insurances, such as health insurance, life insurance, and miscellaneous insurances. It also generates a small amount of revenue from risk management services. The firm act on behalf of its customers seeking insurance coverage from insurance companies. It generates revenue from the provision of insurance brokerage services.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.